VOL. XCIV, NO. 247

★ WIDE MOAT STOCKS COMPARISON ★

NO ADVICE

Stock Comparison

Danaher Corporation vs Eli Lilly and Company

Compare moat strength, market structure, and segment coverage to understand how each company defends its edge.

Danaher Corporation

DHR · New York Stock Exchange

Market cap (USD)$148.1B
Gross margin (TTM)60.9%
Operating margin (TTM)20.9%
Net margin (TTM)14.7%
SectorHealthcare
IndustryMedical - Diagnostics & Research
CountryUS
Data as of2025-12-22
Moat score
77/ 100

Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.

Full stock profile

Dive deeper into Danaher Corporation's moat claims, evidence, and risks.

View DHR analysis

Eli Lilly and Company

LLY · New York Stock Exchange

Market cap (USD)$952.3B
Gross margin (TTM)83.8%
Operating margin (TTM)45.6%
Net margin (TTM)31.7%
SectorHealthcare
IndustryDrug Manufacturers - General
CountryUS
Data as of2026-01-08
Moat score
82/ 100

Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.

Full stock profile

Dive deeper into Eli Lilly and Company's moat claims, evidence, and risks.

View LLY analysis

Comparison highlights

  • Moat score gap: Eli Lilly and Company leads (82 / 100 vs 77 / 100 for Danaher Corporation).
  • Segment focus: Danaher Corporation has 3 segments (41% in Diagnostics); Eli Lilly and Company has 5 segments (65.5% in Cardiometabolic Health).
  • Primary market structure: Oligopoly vs Oligopoly. Pricing power: Moderate vs Strong.
  • Moat breadth: Danaher Corporation has 7 moat types across 3 domains; Eli Lilly and Company has 5 across 3.

Primary market context

Danaher Corporation

Diagnostics

Market

In vitro diagnostics instruments, consumables, software and services (clinical lab, acute care/POC, pathology, molecular diagnostics)

Geography

Global

Customer

Hospitals, physician offices, reference laboratories, pathology labs, critical care settings

Role

IVD device manufacturer and reagent/test supplier + software/services

Revenue share

41%

Eli Lilly and Company

Cardiometabolic Health

Market

Cardiometabolic pharmaceuticals (diabetes, obesity, and related metabolic diseases)

Geography

Global (with U.S. as the largest market)

Customer

Patients via prescribers and payers (commercial/government)

Role

Branded drug developer/manufacturer

Revenue share

65.5%

Side-by-side metrics

Danaher Corporation
Eli Lilly and Company
Ticker / Exchange
DHR - New York Stock Exchange
LLY - New York Stock Exchange
Market cap (USD)
$148.1B
$952.3B
Gross margin (TTM)
60.9%
83.8%
Operating margin (TTM)
20.9%
45.6%
Net margin (TTM)
14.7%
31.7%
Sector
Healthcare
Healthcare
Industry
Medical - Diagnostics & Research
Drug Manufacturers - General
HQ country
US
US
Primary segment
Diagnostics
Cardiometabolic Health
Market structure
Oligopoly
Oligopoly
Market share
n/a
55%-59% (reported)
HHI estimate
n/a
n/a
Pricing power
Moderate
Strong
Moat score
77 / 100
82 / 100
Moat domains
Demand, Supply, Legal
Legal, Supply, Demand
Last update
2025-12-22
2026-01-08

Moat coverage

Shared moat types

Regulated Standards Pipe

Danaher Corporation strengths

Installed Base ConsumablesDesign In QualificationService Field NetworkOperational ExcellenceLearning Curve YieldSuite Bundling

Eli Lilly and Company strengths

IP Choke PointCapacity MoatReputation ReviewsCapex Knowhow Scale

Segment mix

Danaher Corporation segments

Full profile >

Biotechnology

Oligopoly

28.3%

Life Sciences

Oligopoly

30.7%

Diagnostics

Oligopoly

41%

Eli Lilly and Company segments

Full profile >

Cardiometabolic Health

Oligopoly

65.5%

Oncology

Competitive

19.4%

Immunology

Oligopoly

9.8%

Neuroscience

Competitive

3.3%

Other

Competitive

2%

Want the full wide moat stocks list?

Browse the full ranking of wide moat stocks, updated with moat scores and segment context.

View the moat stocks list

Looking for expansion-stage stocks?

Proven models entering the expansion stage with unit economics that work.

View expansion-stage stocks

Curation & Accuracy

This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).

Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.